Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,361,647 papers from all fields of science
Search
Sign In
Create Free Account
furosemide glucuronide
Known as:
beta-D-Glucopyranuronic acid, 1-(5-(aminosulfonyl)-4-chloro-2-((2-furanylmethyl)amino)benzoate)
, furosemide glucuronate
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (1)
Furosemide
analogs & derivatives
Narrower (1)
furosemide acyl glucuronide
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Interaction of human serum albumin with furosemide glucuronide: a role of albumin in isomerization, hydrolysis, reversible binding and irreversible binding of a 1‐O‐acyl glucuronide metabolite
T. Mizuma
,
L. Benet
,
E. Lin
Biopharmaceutics & drug disposition
1999
Corpus ID: 40237344
Furosemide 1‐O‐acyl glucuronide (Fgnd) was reversibly bound to a single class of binding sites on human serum albumin (HSA), and…
Expand
1995
1995
Biliary excretion of furosemide glucuronide in rabbits.
H. Sekikawa
,
N. Yagi
,
+5 authors
L. Benet
Biological and Pharmaceutical Bulletin
1995
Corpus ID: 28410863
Furosemide (F) was administered to rabbits intravenously and intraduodenaly and the biliary excretion was studied. The major…
Expand
1984
1984
FUROSEMIDE GLUCURONIDATION IN INFANTS: IMPLICATIONS OF BETA-GLUCURONIDASE RESISTANT ISOMER FORMATION
A. Rachmel
,
W. Snodgrass
Pediatric Research
1984
Corpus ID: 26045001
Furosemide (F) glucuronidation has been inconclusively suggested to affect the age-related increase in F clearance in infants. A…
Expand
1984
1984
Glucuronidase resistant forms of furosemide glucuronide: Evidence for pH dependent isomerization
A. Rachmel
,
G. A. Hazelton
,
C. Klaassen
,
W. Snodgrass
1984
Corpus ID: 99416456
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE